跳轉至內容
Merck
全部照片(1)

Key Documents

Y0001252

美罗培南三水合物

European Pharmacopoeia (EP) Reference Standard

同義詞:

(1R,5S,6S)-2-[(3S,5S)-5-(二甲氨基羰基)吡咯烷-3-基硫]-6-\ [( R )-1-羟乙基]-1-甲基碳青霉烯-2-烯-3-羧酸三水合物

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H25N3O5S · 3H2O
CAS號碼:
分子量::
437.51
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

meropenem

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

O.O.O.C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O

InChI

1S/C17H25N3O5S.3H2O/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);3*1H2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1

InChI 密鑰

CTUAQTBUVLKNDJ-OBZXMJSBSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Meropenem trihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

美罗培南三水合物是一种对革兰阳性菌和革兰阴性菌均有活性的超广谱 β-内酰胺类抗生素。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Resp. Sens. 1 - Skin Sens. 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Laurens Manning et al.
PloS one, 9(7), e102023-e102023 (2014-07-16)
Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services. We retrospectively reviewed the clinical efficacy and safety of CIs
Angelo Frei et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 26(13), 2852-2858 (2019-12-04)
New antibiotics and innovative approaches to kill drug-resistant bacteria are urgently needed. Metal complexes offer access to alternative modes of action but have only sparingly been investigated in antibacterial drug discovery. We have developed a light-activated rhenium complex with activity
Johannes Zander et al.
Clinical chemistry and laboratory medicine, 53(5), 781-791 (2014-10-11)
Recent studies have demonstrated highly variable blood concentrations of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in critically ill patients with a high incidence of sub-therapeutic levels. Consequently, therapeutic drug monitoring (TDM) of these antibiotics has to be considered, requiring

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務